Veltara doses first patient in Phase 2 study of VLT-201 in ulcerative colitis

Veltara Biosciences today announced that the first patient has been dosed in ASCEND-UC, a randomised, double-blind, placebo-controlled Phase 2 study of VLT-201 in adults with moderate-to-severe ulcerative colitis.

The study will enrol approximately 180 patients across sites in North America and Europe. The primary endpoint is clinical remission at week 12, with mucosal healing and patient-reported outcomes among key secondary endpoints.

"Reaching Phase 2 reflects years of careful translational work," said Dr Priya Raghunathan, Chief Medical Officer. "Our biomarker strategy means this study will tell us something interpretable about the mechanism regardless of outcome."